Modality
mAb
MOA
Anti-Aβ
Target
HER2
Pathway
Notch
MigraineNarcolepsy
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ May 2025
Phase 2Current
NCT06408450
1,886 pts·Narcolepsy
2021-09→2025-05·Recruiting
NCT06567797
124 pts·Narcolepsy
2018-07→TBD·Terminated
2,010 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-0811mo agoPh3 Readout· Narcolepsy
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-05-08 · 11mo ago
Narcolepsy
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06408450 | Phase 2/3 | Narcolepsy | Recruiting | 1886 | LiverFat |
| NCT06567797 | Phase 2/3 | Narcolepsy | Terminated | 124 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 |